Beigene Ltd. clearly liked what it saw in the bispecific antibody platform being developed by Zymeworks Inc. The Beijing-based company is hooking up with Zymeworks in a pair of deals that could end up grossing Zymeworks more than $1 billion.
Biological drugs – monoclonal antibodies, peptides, recombinant proteins and the like – now account for more than 30 percent of all FDA approvals, according to a new study from the Tufts Center for the Study of Drug Development.
Biological drugs – monoclonal antibodies, peptides, recombinant proteins and the like – now account for more than 30 percent of all FDA approvals according to a new study from the Tufts Center for the Study of Drug Development.
SAN DIEGO – At Neurosciences 2018, researchers highlighted mouse experiments and human biomarker studies further straightening the connection between dementia and the cardiovascular system.
SAN DIEGO – As gene therapy advances in the eye and hematopoietic stem cells, researchers are going after the harder-to-treat diseases of the central nervous system (CNS). At the Neurosciences 2018 conference, preclinical data showed the right vector and delivery technique can improve symptoms in mouse models of amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Batten disease as the treatments advance to the clinic.
Medical cannabis companies developing pharmaceuticals have largely focused on using purified cannabinoids as monotherapies to treat neurological diseases. This year, for example, Cambridge, U.K.-based GW Pharma plc gained FDA approval for Epidiolex (cannabidiol) to treat two rare pediatric epilepsies, Dravet syndrome and Lennox-Gastaut syndrome, and others are on GW's heels, developing drugs for epilepsy and pain indications.
Medical cannabis companies developing pharmaceuticals have largely focused on using purified cannabinoids as monotherapies to treat neurological diseases. This year, for example, Cambridge, U.K.-based GW Pharma plc gained FDA approval for Epidiolex (cannabidiol) to treat two rare pediatric epilepsies, Dravet syndrome and Lennox-Gastaut syndrome, and others are on GW's heels, developing drugs for epilepsy and pain indications. (See BioWorld Insight, Oct. 17, 2016.)
Like most medical conferences, the 19th Annual World Conference on Lung Cancer (WCLC) in Toronto was the typical mix of high-profile phase III studies with a large number of earlier-stage programs looking to disrupt the current treatment paradigm.
